Arvinas
Arvinas Inc is an American clinical-stage biopharmaceutical company focused on targeted protein degradation therapeutics. The company utilizes its proprietary PROTAC protein degradation platform to design therapies that harness the body's natural protein disposal system to selectively degrade disease-causing proteins. Revenue is primarily generated through research collaboration agreements, milestone payments, and license options with global biopharmaceutical companies. Core end markets serve oncology and neuroscience patient populations within global healthcare systems. Arvinas occupies a pioneering market position as the originator of PROTAC targeted protein degradation therapies in clinical development. The company is headquartered in New Haven, Connecticut, and its common stock trades on the Nasdaq Global Select Market.
5 of the funds FundTelligence covers report a position in Arvinas.
- Legal name
- Arvinas Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
Funds holding Arvinas
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.15 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.03 % (full portfolio disclosed, October 2026)
- Nordea Internationale aktier — Nordea Funds · 0.01 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.0 % (partially disclosed portfolio, June 2026)